Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies

Area of Science:

• Genomics
• Cancer Biology
• Cell Line Authentication

Background:

• Thyroid cancer cell lines are crucial research models but often misidentified and underutilized in genomic studies.
• Lack of validated cell line datasets hinders progress in understanding thyroid cancer.
• Previous studies have not comprehensively analyzed the genomic landscape of authenticated thyroid cancer cell lines.

Purpose of the Study:

• To provide a validated genomic and transcriptomic dataset of authenticated thyroid cancer cell lines.
• To assess the suitability of these cell lines as models for thyroid cancer research.
• To identify key genomic alterations and transcriptional profiles in thyroid cancer cell lines.

Main Methods:

• Next-generation sequencing (NGS) and transcriptome analysis of 60 authenticated thyroid cancer cell lines.
• Comparison of cell line genomic data with known alterations in primary human thyroid cancers.
• Unsupervised transcriptomic clustering to assess lineage fidelity and differentiation status.

Main Results:

• 94% of cell lines clustered distinctly, confirming their thyroid origin.
• Cell line mutations, including BRAF, RAS, TERT promoter, and TP53, recapitulated those in primary tumors.
• All cell lines exhibited dedifferentiated transcriptional profiles, suitable for modeling advanced thyroid cancer.
• BRAF/RAS-dependent MAPK output correlated with MEK inhibitor sensitivity.
• TP53 heterozygous mutations frequently led to complete p53 loss during in vitro immortalization.

Conclusions:

• The validated cell line dataset serves as a valuable resource for thyroid cancer research.
• These cell lines accurately model key genomic alterations and dedifferentiated states of advanced thyroid cancer.
• The findings will inform future preclinical studies investigating tumor-specific dependencies and therapeutic strategies.